717
Participants
Start Date
July 12, 2022
Primary Completion Date
May 16, 2023
Study Completion Date
May 16, 2023
V116
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PCV15
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
PPSV23
Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
National Taiwan University Hospital ( Site 0800), Taipei
National Cheng Kung University Hospital ( Site 0801), Tainan City
Korea University Ansan Hospital ( Site 0751), Ansan-si
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0400), Milan
Ospedale San Raffaele ( Site 0403), Milan
Centennial Medical Group ( Site 0002), Elkridge
Gachon University Gil Medical Center ( Site 0755), Namdong-gu
Health Research of Hampton Roads, Inc. ( Site 0003), Newport News
Hospital La Princesa ( Site 0515), Madrid
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-Respiratory ( Site 0508), Pozuelo de Alarcón
CHRU de Brest ( Site 0200), Brest
Hospital Internacional Xanit ( Site 0520), Benalmádena
Indago Research & Health Center, Inc ( Site 0005), Hialeah
Alliance for Multispecialty Research, LLC ( Site 0020), Coral Gables
Advanced Medical Research Institute ( Site 0018), Miami
CHU Bordeaux Haut-Leveque ( Site 0202), Pessac
Central Research Associates ( Site 0024), Birmingham
Advanced Medical Research ( Site 0001), Maumee
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0016), Troy
Meridian Clinical Research, LLC ( Site 0009), Norfolk
centre hospitalier lyon sud ( Site 0204), Pierre-Bénite
Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia ( Site 0405), Foggia
Maccabi Healthcare Services ( Site 0306), Jerusalem
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0203), Paris
University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program ( Si, Galveston
Solaris Clinical Research ( Site 0025), Meridian
Fiel Family and Sports Medicine, PC/CCT Research ( Site 0006), Tempe
Lenzmeier Family Medicine/CCT Research ( Site 0008), Glendale
A.O.U. Policlinico Paolo Giaccone ( Site 0402), Palermo
Southland Clinical Research Center ( Site 0026), Fountain Valley
Diablo Clinical Research, Inc. ( Site 0019), Walnut Creek
Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 0302), Sakhnin
Rambam Health Care Campus ( Site 0303), Haifa
Meir Medical Center ( Site 0301), Kfar Saba
Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0304), Ramat Gan
Hadassah Medical Center-Clinical Reaserch Unit ( Site 0300), Jerusalem
Hamilton Medical Research Group ( Site 0114), Hamilton
Milestone Research Inc. ( Site 0104), London
Manna Research Mirabel ( Site 0109), Mirabel
CHU de Québec-Université Laval-Équipe de recherche en vaccination ( Site 0120), Québec
Diex Recherche Sherbrooke Inc. ( Site 0101), Sherbrooke
Maccabi Health Services - Holon ( Site 0305), Holon
Korea University Guro Hospital ( Site 0750), Seoul
PS Clinic ( Site 0700), Fukuoka
Nishikumamoto Hospital ( Site 0701), Kumamoto
The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 0752), Seoul
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0753), Seoul
Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 0754), Seoul
HOSPITAL CLÍNIC DE BARCELONA-Medicina Preventiva i Epidemiologia ( Site 0503), Barcelona
EBA CENTELLES ( Site 0500), Centelles
Hospital Universitari de Bellvitge ( Site 0505), L'Hospitalet de Llobregat
Merck Sharp & Dohme LLC
INDUSTRY